Viking Therapeutics has four phase 3 obesity trials underway for VK2735.
Significant upside exists, but risks and competition remain high.
Phase 3 trials are always interesting because of their proximity to approval and ultimate commercialization of drugs, and particularly so when it involves one with a huge total addressable market (TAM) such as obesity. In addition, the drug in question here, Viking Therapeutics' VK2735, is in a class that already includes one blockbuster drug: Eli Lilly's (NYSE:LLY) tirzepatide (Zepbound for obesity and Mounjaro for obesity with type 2 diabetes), which is approved. All these developments make Viking Therapeutics an attractive stock for investors. Here's why.
The four phase 3 trials comprise two ongoing 78-week trials of VK2735 in subcutaneous form (obesity and obesity with type 2 diabetes; results due in 2027) and two recently started 68-week trials in oral form (results more likely in 2028) for the same indications.
Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »
The trials are part of management's strategy to potentially offer VK2735 across a range of dosing options, including a dual formulation option in which initial weight loss from subcutaneous dosing could be followed by maintenance dosing with a more convenient oral form.
Investors have high hopes for the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, on the back of the success of Eli Lilly's GLP-1/GIP agonist, tirzepatide, and the phase 2 data from the VK2735 trials, which indicate it could achieve a steeper rate of weight loss than tirzepatide. I use cautionary language, as any comparison between two independent trials (let alone a phase 2 and a phase 3) should be accompanied by qualifications.
That said, VK2735 has demonstrated an impressive ability to produce rapid weight loss, as confirmed in a recent small 33-week maintenance study, in which an initial 21-week subcutaneous dose was followed by a subcutaneous maintenance dose over 12 weeks. An exploratory cohort in this trial reported 21.7% weight loss after 33 weeks.
Image source: Getty Images.
The success of this maintenance trial, the first part of a two-part trial, encouraged management to raise a net $547.8 million in a well-received stock offering at $35 and convertible senior notes.
As good as the maintenance trial was, investors should note the second part of the trial (ongoing) is arguably more important, as it involves an initial 21-week subcutaneous dose followed by oral dosing over 12 weeks. The point is that phase 2 of oral VK2735 had questionable tolerability (a 20% discontinuation rate due to adverse events in the treated group), and Viking will have to demonstrate better tolerability in the maintenance trial and the phase 3 oral trials.
I previously outlined the math showing how a $10,000 investment in Viking Therapeutics could grow to $47,800 in 2030; it follows that a $1,000 investment could grow to $4,780.
That's the bullish case scenario, but investors always need to consider the risk that the phase 3 trials will fail to meet their primary endpoints or could deliver efficacy or tolerability data that negatively impacts the commercial appeal of the drug, not least because it's a highly competitive market with Eli Lilly, Novo Nordisk, and others developing rival drugs.
Image source: Getty Images.
The strongest case for the stock isn't that VK2735 will become a blockbuster drug, but rather that even if it captures only a relatively small share of the market, it will be enough to drive a significant increase in the share price of the $3.5 billion market-cap company.
It could do so provided its phase 3 trials deliver on the weight loss generated in the phase 2 trials and, ideally, some improved tolerability data in the maintenance study, which is due to report results next year. Investors will need to be patient, as the oral trial results (crucial to the dual formulation strategy) aren't likely to be available until 2028. The long-term potential is obvious, and Viking Therapeutics could always be acquired by a larger company seeking a late-stage obesity drug candidate.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*
Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 18, 2026.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly, Novo Nordisk, and Viking Therapeutics. The Motley Fool has a disclosure policy.